Matches in SemOpenAlex for { <https://semopenalex.org/work/W2526316615> ?p ?o ?g. }
- W2526316615 endingPage "71672" @default.
- W2526316615 startingPage "71660" @default.
- W2526316615 abstract "// Kathleen A. Bridges 1 , Xingxing Chen 1, 4 , Huifeng Liu 1 , Crosby Rock 1 , Thomas A. Buchholz 2 , Stuart D. Shumway 3 , Heath D. Skinner 2 , Raymond E. Meyn 1 1 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Merck Research Laboratories, Boston, MA, USA 4 Present address: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China Correspondence to: Raymond E. Meyn, email: rmeyn@mdanderson.org Keywords: radiation, Chk1, p53-dependent, MK-8776, DNA damage Received: July 20, 2016 Accepted: September 20, 2016 Published: September 28, 2016 ABSTRACT Radiotherapy is commonly used to treat a variety of solid tumors but improvements in the therapeutic ratio are sorely needed. The aim of this study was to assess the Chk1 kinase inhibitor, MK-8776, for its ability to radiosensitize human tumor cells. Cells derived from NSCLC and HNSCC cancers were tested for radiosensitization by MK-8776. The ability of MK-8776 to abrogate the radiation-induced G2 block was determined using flow cytometry. Effects on repair of radiation-induced DNA double strand breaks (DSBs) were determined on the basis of rad51, γ-H2AX and 53BP1 foci. Clonogenic survival analyses indicated that MK-8776 radiosensitized p53-defective tumor cells but not lines with wild-type p53. Abrogation of the G2 block was evident in both p53-defective cells and p53 wild-type lines indicating no correlation with radiosensitization. However, only p53-defective cells entered mitosis harboring unrepaired DSBs. MK-8776 appeared to inhibit repair of radiation-induced DSBs at early times after irradiation. A comparison of MK-8776 to the wee1 inhibitor, MK-1775, suggested both similarities and differences in their activities. In conclusion, MK-8776 radiosensitizes tumor cells by mechanisms that include abrogation of the G2 block and inhibition of DSB repair. Our findings support the clinical evaluation of MK-8776 in combination with radiation." @default.
- W2526316615 created "2016-10-07" @default.
- W2526316615 creator A5012720004 @default.
- W2526316615 creator A5013558767 @default.
- W2526316615 creator A5015094097 @default.
- W2526316615 creator A5045529171 @default.
- W2526316615 creator A5057447059 @default.
- W2526316615 creator A5060146041 @default.
- W2526316615 creator A5078529824 @default.
- W2526316615 creator A5090093028 @default.
- W2526316615 date "2016-09-28" @default.
- W2526316615 modified "2023-10-12" @default.
- W2526316615 title "MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells" @default.
- W2526316615 cites W1594035260 @default.
- W2526316615 cites W1628408467 @default.
- W2526316615 cites W163730063 @default.
- W2526316615 cites W1752089945 @default.
- W2526316615 cites W1840165714 @default.
- W2526316615 cites W1922143413 @default.
- W2526316615 cites W1965239527 @default.
- W2526316615 cites W1973388314 @default.
- W2526316615 cites W1977437589 @default.
- W2526316615 cites W1979803759 @default.
- W2526316615 cites W1983447284 @default.
- W2526316615 cites W2020495169 @default.
- W2526316615 cites W2027445756 @default.
- W2526316615 cites W2034646939 @default.
- W2526316615 cites W2039925492 @default.
- W2526316615 cites W2049877855 @default.
- W2526316615 cites W2051744391 @default.
- W2526316615 cites W2054471320 @default.
- W2526316615 cites W2055725338 @default.
- W2526316615 cites W2074692995 @default.
- W2526316615 cites W2079687844 @default.
- W2526316615 cites W2082861064 @default.
- W2526316615 cites W2086131247 @default.
- W2526316615 cites W2086255242 @default.
- W2526316615 cites W2094665364 @default.
- W2526316615 cites W2096293110 @default.
- W2526316615 cites W2097173890 @default.
- W2526316615 cites W2101191739 @default.
- W2526316615 cites W2102815568 @default.
- W2526316615 cites W2104855205 @default.
- W2526316615 cites W2105427724 @default.
- W2526316615 cites W2105590267 @default.
- W2526316615 cites W2109554640 @default.
- W2526316615 cites W2111222453 @default.
- W2526316615 cites W2111546308 @default.
- W2526316615 cites W2113603158 @default.
- W2526316615 cites W2113684644 @default.
- W2526316615 cites W2116964110 @default.
- W2526316615 cites W2117015521 @default.
- W2526316615 cites W2118023637 @default.
- W2526316615 cites W2119363024 @default.
- W2526316615 cites W2124529603 @default.
- W2526316615 cites W2133150002 @default.
- W2526316615 cites W2133613025 @default.
- W2526316615 cites W2135946515 @default.
- W2526316615 cites W2140990686 @default.
- W2526316615 cites W2142325694 @default.
- W2526316615 cites W2144455387 @default.
- W2526316615 cites W2145200068 @default.
- W2526316615 cites W2146498297 @default.
- W2526316615 cites W2149795092 @default.
- W2526316615 cites W2153635460 @default.
- W2526316615 cites W2159353995 @default.
- W2526316615 cites W2161171953 @default.
- W2526316615 cites W2167397744 @default.
- W2526316615 cites W2410629805 @default.
- W2526316615 doi "https://doi.org/10.18632/oncotarget.12311" @default.
- W2526316615 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5342109" @default.
- W2526316615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27690219" @default.
- W2526316615 hasPublicationYear "2016" @default.
- W2526316615 type Work @default.
- W2526316615 sameAs 2526316615 @default.
- W2526316615 citedByCount "30" @default.
- W2526316615 countsByYear W25263166152017 @default.
- W2526316615 countsByYear W25263166152018 @default.
- W2526316615 countsByYear W25263166152019 @default.
- W2526316615 countsByYear W25263166152020 @default.
- W2526316615 countsByYear W25263166152021 @default.
- W2526316615 countsByYear W25263166152022 @default.
- W2526316615 countsByYear W25263166152023 @default.
- W2526316615 crossrefType "journal-article" @default.
- W2526316615 hasAuthorship W2526316615A5012720004 @default.
- W2526316615 hasAuthorship W2526316615A5013558767 @default.
- W2526316615 hasAuthorship W2526316615A5015094097 @default.
- W2526316615 hasAuthorship W2526316615A5045529171 @default.
- W2526316615 hasAuthorship W2526316615A5057447059 @default.
- W2526316615 hasAuthorship W2526316615A5060146041 @default.
- W2526316615 hasAuthorship W2526316615A5078529824 @default.
- W2526316615 hasAuthorship W2526316615A5090093028 @default.
- W2526316615 hasBestOaLocation W25263166151 @default.
- W2526316615 hasConcept C117262875 @default.
- W2526316615 hasConcept C121608353 @default.
- W2526316615 hasConcept C126322002 @default.
- W2526316615 hasConcept C143998085 @default.
- W2526316615 hasConcept C502942594 @default.